Urology in the Lab: Researchers link EBV to multiple sclerosis ...

"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD. In this video, Jindan Yu, MD, PhD, ...

Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...

Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...

CMS has selected 15 additional drugs for Medicare Part D price negotiations, aiming to lower healthcare costs for enrollees. The Inflation Reduction Act allows Medicare to negotiate drug prices, with ...

A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing ...

"My biggest hope for people reading this review is to understand that there are some golden opportunities for research," says Laura Bukavina, MD, MPH, MSc. Isali: I think our review mainly highlighted ...

PSMA PET imaging can lead to significant stage migration in mHSPC, affecting treatment decisions and patient outcomes. 40.3% of patients experienced stage changes with PSMA PET, including shifts from ...

"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says ...

ImmunityBio aims to expand Anktiva's approval for BCG-unresponsive NMIBC with papillary tumors, potentially reducing radical cystectomy rates. The QUILT-3.032 trial demonstrated promising disease-free ...

Mona Lisa 2.0 receives CE certification, enabling use in 32 European countries for prostate cancer procedures. The platform offers advanced positioning and software for real-time adjustments, ...

“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder ...